Article
NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
Leukemia & lymphoma - 1 Dec 2014
Chiaretti Sabina, Marinelli Marilisa, Del Giudice Ilaria, Bonina Silvia, Piciocchi Alfonso, Messina Monica, Vignetti Marco, Rossi Davide, Di Maio Valeria, Mauro Francesca Romana, Guarini Anna, Gaidano Gianluca, Foà Robin
Abstract excerpt
In chronic lymphocytic leukemia, NOTCH1, SF3B1, BIRC3 and TP53 disruptions are recurrent and affect survival. To define their incidence and clinical impact in patients undergoing first-line treatment, we evaluated 163 cases enrolled in the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) LLC0405 protocol (fludarabine plus alemtuzumab or fludarabine plus cyclophosphamide), for young patients, or in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.